PCI High Potent Manufacturing
LB Bohle – 10.06.2025
Temax_Krautz

Current Edition

Current Edition

Subsection - CDMO

Examining how innovative technologies, integrated manufacturing approaches and AI are shaping manufacturing.

Continue reading

Subsection - Injectables

Exploring advances in injectable drug delivery and sterile manufacturing, designed to improve patient-centric delivery.

Continue reading

Subsection - Neurodegenerative Diseases

Exploring emerging approaches to neurodegenerative disease research and treatment.

Continue reading

Subsection - Nasal & Pulmonary

Highlighting how advances in nasal and pulmonary drug delivery, formulation, devices and analytics are enabling more complex therapies.

Continue reading

Advertisement

CPHI 2027
DDL 2026

Advertisement

Nipro August 26

Advertisement

Merxin March 2026

Advertisement

Aurisco 300×250

Advertisement

Lifecore Biomedical

Aptar Stelmi features PremiumCoat™ at CPhI/InnoPack 2015, from 13-15 October, in Madrid, Spain

Coated stoppers for sensitive and high-value injectables
 
 
Aptar Stelmi, the industry’s trusted global partner, providing premium elastomeric closure systems for injectables, announces a new addition to its broad portfolio of products with the introduction of a novel range of coated stoppers calledPremiumCoat™, designed for the protection of sensitive and high-value drugs, including biopharmaceuticals.
 
Sensitive and high-value injectables, a dynamic market
 
Sensitive and high-value injectables encompass complex and potent drugs manufactured by chemical synthesis and biological agents engineered in a living system such as a microorganism, plant or animal cell. They include cytotoxic drugs used in cancer therapies, novel vaccines, blood derivatives, hormones and many compounds used to treat auto-immune diseases, including monoclonal antibodies.
 
The market for biologics represents 20% of the global drug market with growth at a CAGR of 10% in 2010-2015, twice that of the global drug market.
 
Sensitive and high-value injectables require premium components
 
Sensitive and high-value injectables are fragile by nature. Therefore maintaining the integrity of the container closure while minimizing interaction between the drug compound(s) and the component constituents is a challenge.
 
Conventional elastomeric closure systems may not be an optimal solution for these fragile drugs.
 
PremiumCoat™ is a novel range of elastomeric stoppers developed by Aptar Stelmi. The surface of the elastomer is coated during manufacturing with a thin fluoropolymer film. This coating acts as an effective barrier to many of the extractables and leachables that can be released from the elastomer and contaminate the drug. As a result, compatibility of the drug and the closure is significantly superior with PremiumCoat™ stoppers.
 
“Aptar Stelmi is looking forward to presenting PremiumCoat™ at the upcoming CPhI/InnoPack 2015. The past three years we have spent developing the technology and then preparing for this new product launch have been very exciting. PremiumCoat™ is the first product in our range of innovative solutions for high-value injectable drugs,” said Ghislain Fournier, Industrial & Technical Director, Aptar Stelmi.
 
 
 

Advertisement

MedPharm 16/07

Advertisement

Biopharma group march 2026

Advertisement

Silgan March 2026

Advertisement

Terumo 06/26

Advertisement

Scott Pharma – 25.03.2025

Advertisement

Bespak

Advertisement

Solstice

Advertisement

Bachem skyscraper
Tjoapack
Aptar – 08/01/2026